About: Continued In-Hospital Angiotensin-Converting Enzyme Inhibitor and Angiotensin II Receptor Blocker Use in Hypertensive COVID-19 Patients Is Associated With Positive Clinical Outcome

Facets (new session)
Description
Metadata
Settings
- owl:sameAs
- Inference Rule:

About: Continued In-Hospital Angiotensin-Converting Enzyme Inhibitor and Angiotensin II Receptor Blocker Use in Hypertensive COVID-19 Patients Is Associated With Positive Clinical Outcome Goto Sponge NotDistinct Permalink

An Entity of Type : schema:ScholarlyArticle, within Data Space : wasabi.inria.fr associated with source document(s)

Attributes	Values
type	Academic Article research paper schema:ScholarlyArticle
isDefinedBy	Covid-on-the-Web dataset
title	Continued In-Hospital Angiotensin-Converting Enzyme Inhibitor and Angiotensin II Receptor Blocker Use in Hypertensive COVID-19 Patients Is Associated With Positive Clinical Outcome
Creator	Hou, Wei Duong, Tim Li, Haifang Richman, Paul Singer, Adam Chow, Kenneth Lam, Katherine Mallipattu, Sandeep Skopicki, Hal Vo, Jonathan
source	Medline; PMC
abstract	BACKGROUND: This study investigated continued and discontinued use of angiotensin-converting enzyme inhibitors (ACEi) or angiotensin II receptor blockers (ARB) during hospitalization of 614 hypertensive laboratory-confirmed COVID-19 patients. METHODS: Demographics, comorbidities, vital signs, laboratory data, and ACEi/ARB usage were analyzed. To account for confounders, patients were substratified by whether they developed hypotension and acute kidney injury (AKI) during the index hospitalization. RESULTS: Mortality (22% vs 17%, P > .05) and intensive care unit (ICU) admission (26% vs 12%, P > .05) rates were not significantly different between non-ACEi/ARB and ACEi/ARB groups. However, patients who continued ACEi/ARBs in the hospital had a markedly lower ICU admission rate (12% vs 26%; P = .001; odds ratio [OR] = 0.347; 95% confidence interval [CI], .187–.643) and mortality rate (6% vs 28%; P = .001; OR = 0.215; 95% CI, .101–.455) compared to patients who discontinued ACEi/ARB. The odds ratio for mortality remained significantly lower after accounting for development of hypotension or AKI. CONCLUSIONS: These findings suggest that continued ACEi/ARB use in hypertensive COVID-19 patients yields better clinical outcomes.
has issue date	2020-07-23(xsd:dateTime)
bibo:doi	10.1093/infdis/jiaa447
bibo:pmid	32702098
has license	no-cc
schema:url	https://doi.org/10.1093/infdis/jiaa447
resource representing a document's title	Continued In-Hospital Angiotensin-Converting Enzyme Inhibitor and Angiotensin II Receptor Blocker Use in Hypertensive COVID-19 Patients Is Associated With Positive Clinical Outcome
has PubMed Central identifier	PMC7454718
has PubMed identifier	32702098
schema:publication	J Infect Dis
resource representing a document's body	covid:PMC7454718#body_text
is schema:about of	named entity 'Enzyme' named entity 'HYPERTENSIVE' named entity 'CONTINUED' named entity 'ANGIOTENSIN-CONVERTING ENZYME INHIBITOR' named entity 'Angiotensin-Converting Enzyme Inhibitor' named entity 'statistically significant' named entity 'informed consent' named entity 'hypertensive' named entity 'comorbidities' named entity 'upregulate' named entity 'statistical analyses' named entity 'clinical outcomes' named entity 'correction for multiple comparisons' named entity 'angiotensin' named entity 'COVID-19' named entity 'ACEi' named entity 'ACEi' named entity 'ICU' named entity 'COVID' named entity 'COVID-19' named entity 'IBM Corporation' named entity 'IQR' named entity 'COVID-19' named entity 'sample size' named entity 'propensity score matching' named entity 'ICU' named entity 'ICU' named entity 'significant difference' named entity 'sample size' named entity 'proinflammatory' named entity 'ARBs' named entity 'ICU' named entity 'ARBs' named entity 'ARBs' named entity 'ACEi' named entity 'ARBs' named entity 'ACEi' named entity 'ACEi' named entity 'emergency department' named entity 'ACEi' named entity 'ACEi' named entity 'SARS-CoV-2' named entity 'COVID' named entity 'ARBs' named entity 'hypotension' named entity 'ACEi' named entity '95% confidence interval' named entity 'ACEi' named entity 'hypertensive' named entity 'clinical care' named entity 'ICU' named entity 'ACEi' named entity 'ACEi' named entity 'correction for multiple comparisons' named entity 'clinical practice' named entity 'ACEi' named entity 'heart failure' named entity 'ICU' named entity 'median age' named entity 'ACEi' named entity 'asthma' named entity 'ACEi' named entity 'hypertension' named entity 'ACEi' named entity 'ACEi' named entity 'hypertensive' named entity 'hypertensive' named entity 'ACEi' named entity 'ARBs' named entity 'ACEi' named entity 'COVID' named entity 'ACEi' named entity 'ACEi'

Faceted Search & Find service v1.13.91 as of Mar 24 2020

Alternative Linked Data Documents: Sponger | ODE Content Formats:

RDF

ODATA

Microdata

About

OpenLink Virtuoso version 07.20.3229 as of Jul 10 2020, on Linux (x86_64-pc-linux-gnu), Single-Server Edition (94 GB total memory)
Data on this page belongs to its respective rights holders.
Virtuoso Faceted Browser Copyright © 2009-2025 OpenLink Software